Albedo to buy majority stake in Taiwanese aesthetic medicine group for S$18.9m
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
STEEL trading company Albedo Limited said it has agreed to acquire a majority stake in a Taiwanese aesthetic medicine group, which will serve as a "springboard" for its expansion into China's fast-growing healthcare market.
Under a conditional sale and purchase agreement inked on Thursday, Albedo agreed to buy a 51 per cent stake in China iMyth Company Pte Ltd from China Medical Investments Company Pte Limited (CMIC) for S$18.9 million. The remaining 49 per cent of China iMyth is owned by Taiwan's plastic surgeon expert Chung Yih-Chen, who is also its managing director.
The payment will comprise S$12 million in cash and 550 million shares at an issue price of 1.25 cents per share.
Albedo CEO Tai Kok Chuan said: "We have been exploring opportunities to diversify our business in the wake of increased competition and softening demand in our steel trading business. We believe that a stake in China iMyth will create value for shareholders and enhance Albedo's long-term viability."
Copyright SPH Media. All rights reserved.
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
